News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA Yael L. Maxwell March 09, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2021 Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions L.A. McKeown May 21, 2021
News Conference News ACC 2020 TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients Todd Neale March 31, 2020
News Conference News ACC 2020 PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years Michael O'Riordan March 30, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019
News Conference News ACC 2019 SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI Michael O'Riordan March 18, 2019
News Conference News ACC 2019 Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI Yael L. Maxwell March 18, 2019
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2015 Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease L.A. McKeown March 15, 2015
News Conference News ACC 2012 Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES Jason Kahn March 24, 2012